Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Neurooncol ; 163(3): 565-575, 2023 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-37402093

RESUMEN

PURPOSE: H3K27 altered pediatric pontine diffuse midline gliomas (pDMG) have a poor prognosis, and conventional treatments offer limited benefits. However, recent advancements in molecular evaluations and targeted therapies have shown promise. The aim of this retrospective analysis was to evaluate the effectiveness of German-sourced ONC201, a selective antagonist of dopamine receptor DRD2, for the treatment of pediatric H3K27 altered pDMGs. METHODS: Pediatric patients with H3K27 altered pDMG treated between January 2016 and July 2022 were included in this retrospective analysis. Tissue samples were acquired from all patients via stereotactic biopsy for immunohistochemistry and molecular profiling. All patients received radiation treatment with concurrent temozolomide, and those who could acquire GsONC201 received it as a single agent until progression. Patients who could not obtain GsONC201 received other chemotherapy protocols. RESULTS: Among 27 patients with a median age of 5.6 years old (range 3.4-17.9), 18 received GsONC201. During the follow-up period, 16 patients (59.3%) had progression, although not statistically significant, the incidence of progression tended to be lower in the GsONC201 group. The median overall survival (OS) of the GsONC201 group was considerably longer than of the non-GsONC201 group (19.9 vs. 10.9 months). Only two patients receiving GsONC201 experienced fatigue as a side effect. 4 out of 18 patients in the GsONC201 group underwent reirradiation after progression. CONCLUSION: In conclusion, this study suggests that GsONC201 may improve OS in pediatric H3K27-altered pDMG patients without significant side effects. However, caution is warranted due to retrospective design and biases, highlighting the need for further randomized clinical studies to validate these findings.


Asunto(s)
Neoplasias del Tronco Encefálico , Glioma , Niño , Humanos , Preescolar , Adolescente , Estudios Retrospectivos , Glioma/patología , Imidazoles/uso terapéutico , Piridinas/uso terapéutico , Neoplasias del Tronco Encefálico/tratamiento farmacológico , Neoplasias del Tronco Encefálico/radioterapia
2.
Nutr Cancer ; 69(3): 402-407, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28107040

RESUMEN

BACKGROUND: Recent studies claim that apoptosis may explain immune dysfunction observed in malnutrition. OBJECTIVE: The objective of this study was to determine the effect of malnutrition on apoptotic functions of phagocytic cells in acute lymphoblastic leukemia (ALL). MATERIALS AND METHODS: Twenty-eight ALL patients (13 with malnutrition) and thirty controls were enrolled. Neutrophil and mononuclear cell apoptosis of ALL patients and the control group were studied on admission before chemotherapy and repeated at a minimum of three months after induction of chemotherapy or when the nutritional status of leukemic children improved. RESULTS: The apoptotic functions of both ALL groups on admission were significantly lower than those of the control group. The apoptotic functions were lower in ALL patients with malnutrition than those in ALL patients without malnutrition, but this was not statistically significant. The repeated apoptotic functions of both ALL groups were increased to similar values with the control group. This increase was found to be statistically significant. CONCLUSIONS: The apoptotic functions in ALL patients were not found to be affected by malnutrition. However, after dietary intervention, increased apoptotic functions in both ALL patient groups deserve mentioning. Dietary intervention should always be recommended as malnutrition or cachexia leads to multiple complications. Enhanced apoptosis might originate also from remission state of cancer.


Asunto(s)
Apoptosis , Desnutrición/complicaciones , Neutrófilos/patología , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaciones , Adolescente , Estudios de Casos y Controles , Niño , Preescolar , Dieta , Femenino , Humanos , Lactante , Masculino , Estado Nutricional , Estudios Prospectivos
3.
Pediatr Dermatol ; 32(6): e263-6, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26446280

RESUMEN

Hoyeraal-Hreidarsson syndrome is a rare telomere biology disorder that is recognized as a severe variant of dyskeratosis congenita. We present a Libyan boy with hematologic and neurologic abnormalities with typical dermatologic manifestations of dyskeratosis congenita. Death usually occurs before the age of 4 years as a result of pancytopenia or malignant transformation of mucocutaneous lesions. The boy presented survived longer than 5 years. Early recognition and appropriate genetic counseling are crucial because of the high mortality of this genetic disorder.


Asunto(s)
Disqueratosis Congénita/diagnóstico , Retardo del Crecimiento Fetal/diagnóstico , Discapacidad Intelectual/diagnóstico , Microcefalia/diagnóstico , Preescolar , Diagnóstico Diferencial , Disqueratosis Congénita/genética , Retardo del Crecimiento Fetal/genética , Humanos , Discapacidad Intelectual/genética , Imagen por Resonancia Magnética , Masculino , Microcefalia/genética , Fenotipo , Telómero/genética
4.
Support Care Cancer ; 20(2): 385-93, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21416159

RESUMEN

PURPOSE: The effectiveness of carboplatin and vincristine chemotherapy in the treatment of low-grade glioma (LGG) is well established. However, carboplatin hypersensitivity reactions (CHR) are a major problem leading to premature cessation of therapy. We aimed to investigate the clinical features and the management strategies in CHR, retrospectively. METHOD: Fifty LGG patients treated between October 1997 and January 2008 with carboplatin and vincristine were included in the study. Clinical features, management strategies, influence of demographic factors on CHR, and success rate in terms of continuation with carboplatin therapy were evaluated. RESULTS: CHR were observed in 20 (40%) patients and grade I reactions were the most common. The median number of carboplatin doses administered at the first episode of CHR was nine (range 1-41). Only younger age was found to be correlated with the presence of CHR. Nine patients had carboplatin desensitization protocol; eight patients were given various combinations of premedication while three had no modification. Treatment was terminated in five patients due to CHR. Overall success rate was 75%. CONCLUSIONS: This is the largest single-center study conducted to investigate the frequency and the management strategies in patients with CHR who were treated with the same chemotherapy protocol for LGG. Premedication and desensitization were the preferred modifications in case of CHR. Overall, the success rate for carboplatin continuation is high in comparison to previous studies. Carboplatin can be continued successfully in many cases with CHR if reactions are managed in a timely fashion.


Asunto(s)
Antineoplásicos/efectos adversos , Carboplatino/efectos adversos , Hipersensibilidad a las Drogas/etiología , Glioma/tratamiento farmacológico , Adolescente , Factores de Edad , Antineoplásicos/uso terapéutico , Carboplatino/uso terapéutico , Niño , Preescolar , Desensibilización Inmunológica/métodos , Hipersensibilidad a las Drogas/epidemiología , Femenino , Glioma/patología , Humanos , Lactante , Masculino , Estudios Retrospectivos , Resultado del Tratamiento , Vincristina/administración & dosificación
5.
Turk J Pediatr ; 54(3): 294-7, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23094542

RESUMEN

Embolization is a rare but serious complication of venous central catheters in pediatric oncology. The reported cases in the literature are due in common to catheter ruptures. The most common cause is constant compression of the costoclavicular arch, known as "pinch-off" syndrome. We report a seven-year-old boy in whom embolization occurred as a late complication. Difficulty in the dissection of dense collagen periportal fibrosis was the main problem during the extraction session. The embolization occurred 10 months later. In an elective setting, percutaneous retrieval techniques were used successfully to extract the catheter fragments, and full recovery was achieved.


Asunto(s)
Cateterismo Venoso Central/instrumentación , Catéteres de Permanencia/efectos adversos , Migración de Cuerpo Extraño/terapia , Antineoplásicos/administración & dosificación , Niño , Migración de Cuerpo Extraño/diagnóstico , Humanos , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Tomografía Computarizada por Rayos X
7.
Pediatr Hematol Oncol ; 27(6): 422-34, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20578809

RESUMEN

This study aimed to document outcome of invasive respiratory aspergillosis (IRA) in pediatric malignancy patients. Patients with febrile neutropenia episodes followed between January 2003 and May 2007 were enrolled. Antifungal therapy was added to those who were still febrile on the 5th day of febrile neutropenia treatment. Patients were screened with computerized tomographies. IRA was identified in 22 of 98 patients. There were 13 males and the mean age was 97 months. Proven infection was established in 3, probable in 7, and possible in 12 patients. Liposomal amphotericin B was administered to all patients and was successful in 10 patients. Modifications with caspofungin or voriconazole were done in liposomal amphotericin B failures. The median duration of antifungal therapy was 5.5 months. The median follow-up time was 29 months. There was no evidence of IRA in 12 patients after completion of cancer chemotherapy. Six patients died due to underlying disease, whereas IRA was either in remission or stable disease. Four patients were lost due to IRA. The remission rate for IRA was 82%. Survival at 37 months was 55% (95% confidence interval 25-47 months). The amount of time that absolute neutrophil count after initiation of treatment for IRA remained at zero was found to be an independent prognostic factor on survival (P = .01). These results suggest that early diagnosis and aggressive treatment may increase the successful outcome of IRA.


Asunto(s)
Antifúngicos/uso terapéutico , Aspergilosis Pulmonar/tratamiento farmacológico , Anfotericina B/uso terapéutico , Caspofungina , Niño , Diagnóstico Precoz , Equinocandinas/uso terapéutico , Femenino , Fiebre/tratamiento farmacológico , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/microbiología , Humanos , Lipopéptidos , Masculino , Neutropenia/tratamiento farmacológico , Pronóstico , Aspergilosis Pulmonar/diagnóstico , Aspergilosis Pulmonar/etiología , Pirimidinas/uso terapéutico , Estudios Retrospectivos , Resultado del Tratamiento , Triazoles/uso terapéutico , Voriconazol
8.
Turk J Pediatr ; 52(3): 325-9, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20718195

RESUMEN

Although primary bronchopulmonary fibrosarcoma is a rare tumor, it may be characterized by the symptoms of acute respiratory distress occurring during the first moments of life in a newborn. It is one of the leading congenital malignant neoplasms of the lung, but is considered a borderline tumor since its biological behavior is much more favorable than that of adult fibrosarcomas. In the absence of metastases, complete resection is curative. Histopathological diagnosis is not simple, as the microscopic characteristics may be confused with benign fibromatosis or malignant mesenchymal neoplasms. In this case report, we present a case of congenital pulmonary spindle cell tumor showing the features of fibrosarcoma, and we discuss the differential diagnosis of spindle cell lesions localized within the thorax.


Asunto(s)
Fibrosarcoma/congénito , Hipoglucemia/etiología , Neoplasias Pulmonares/congénito , Insuficiencia Respiratoria/etiología , Fibrosarcoma/complicaciones , Fibrosarcoma/diagnóstico , Fibrosarcoma/patología , Fibrosarcoma/cirugía , Humanos , Recién Nacido , Neoplasias Pulmonares/complicaciones , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/cirugía
9.
Turk J Haematol ; 27(4): 257-62, 2010 Dec 05.
Artículo en Inglés | MEDLINE | ID: mdl-27263739

RESUMEN

OBJECTIVE: This study analyzes the clinical and laboratory findings of children with primary hemophagocytic lymphohistiocytosis (HLH) followed in various referral centers of Turkey. METHODS: A simple three-page questionnaire prepared by the Turkish Histiocyte Study Group was used for documentation of patient data. RESULTS: Age at diagnosis varied from 0.6 to 78 months (median±SD, 16.5±26.1). Sex distribution was almost equal (F/M=10/12). The frequencies of parental consanguinity and sibling death in the family history were 100% and 81.1%, respectively. The most common clinical findings were hepatomegaly (100%) and fever (95%). The most common laboratory findings were anemia (100%), hyperferritinemia (100%) and thrombocytopenia (90.9%). Triglyceride and total bilirubin levels in the deceased versus surviving group appear to be high (triglyceride: 394±183 mg/dl, 289±7 mg/dl; total bilirubin: 2.7±6.9 mg/dl, 0.5±1.2 mg/dl, respectively). CONCLUSION: We concluded that fever, hepatosplenomegaly, anemia, thrombocytopenia, and hyperferritinemia are the most common clinical and laboratory findings in primary HLH. Increased triglyceride and total bilirubin level at the time of diagnosis might be an indicator of poor prognosis in HLH.

10.
J Pediatr Endocrinol Metab ; 22(4): 363-8, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19554811

RESUMEN

Ectopic ACTH syndrome (EAS) is extremely rare in the pediatric age group. Sarcomatous tumors causing EAS are even rarer. We report a 9 year-old girl presenting with Cushing's syndrome caused by ectopic ACTH production by a Ewing's sarcoma. This case illustrates that rapid appearance of Cushingoid symptoms, absence of growth retardation and the presence of hypokalemia are suggestive clues for ectopic ACTH production as the source of Cushing's syndrome.


Asunto(s)
Síndrome de ACTH Ectópico/complicaciones , Hormona Adrenocorticotrópica/metabolismo , Síndrome de Cushing/etiología , Sarcoma de Ewing/complicaciones , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Niño , Síndrome de Cushing/tratamiento farmacológico , Ciclofosfamida/uso terapéutico , Doxorrubicina/uso terapéutico , Femenino , Humanos , Neoplasias Retroperitoneales/complicaciones , Neoplasias Retroperitoneales/tratamiento farmacológico , Sarcoma de Ewing/tratamiento farmacológico , Vincristina/uso terapéutico
11.
APMIS ; 116(2): 163-6, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18321370

RESUMEN

Acute megakaryoblastic leukemia is a relatively rare form of acute leukemia that has heterogeneous blast morphology and karyotypic abnormalities. An 8-month-old boy with a retroperitoneal mass was diagnosed as having acute megakaryoblastic leukemia that initially presented as small round cell tumor of childhood. Bone marrow aspiration showed syncytial groups of atypical medium sized cells with scant cytoplasm and fine nuclear chromatin. Retroperitoneal mass biopsy showed several lymph nodes with cohesive clusters of neoplastic cells that demonstrated expression of Factor VIII. Flow cytometric analysis of the second bone marrow aspiration showed CD 61 positivity. Karyotypic analysis of bone marrow cells showed a novel translocation, (1;5)(q21;p13).


Asunto(s)
Cromosomas Humanos Par 1 , Cromosomas Humanos Par 5 , Leucemia Megacarioblástica Aguda/genética , Neoplasias Retroperitoneales/genética , Translocación Genética , Células de la Médula Ósea/patología , Factor VIII/análisis , Resultado Fatal , Humanos , Inmunohistoquímica , Lactante , Cariotipificación , Leucemia Megacarioblástica Aguda/diagnóstico , Leucemia Megacarioblástica Aguda/patología , Leucemia Megacarioblástica Aguda/terapia , Masculino , Neoplasias Retroperitoneales/diagnóstico , Neoplasias Retroperitoneales/patología , Neoplasias Retroperitoneales/terapia
12.
Pediatr Blood Cancer ; 50(4): 881-3, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17417791

RESUMEN

Role of Positron Emission Tomography (PET) with F-18-2-fluoro-2-deoxy-D-glucose (FDG) in staging of Hodgkin disease is well established despite several controversies. We report a Stage III Hodgkin lymphoma patient with false positive FDG-PET/CT results. Seven-year-old male with Hodgkin lymphoma was in remission at end of chemotherapy. At third and fourth month of postchemotherapy follow-up, increased Gallium uptake and positive FDG-PET/CT in right lower quadrant of abdomen was observed. Open biopsy revealed lymphoid hyperplasia. He has been followed for 21 months without any evidence of disease. Despite its documented benefit, we believe that results of FDG-PET/CT should be interpreted with great caution in order to avoid unnecessary interventions.


Asunto(s)
Glucosa-6-Fosfato/análogos & derivados , Enfermedad de Hodgkin/diagnóstico , Recurrencia Local de Neoplasia/diagnóstico , Tomografía de Emisión de Positrones , Radiofármacos , Tomografía Computarizada por Rayos X , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Niño , Reacciones Falso Positivas , Galio , Enfermedad de Hodgkin/tratamiento farmacológico , Humanos , Masculino , Estadificación de Neoplasias
13.
Turk J Haematol ; 25(3): 152-4, 2008 Sep 05.
Artículo en Inglés | MEDLINE | ID: mdl-27264709

RESUMEN

It is known that clonal chromosomal changes in childhood ALL are nonrandom and important markers for diagnosis, prognosis and relaps. In this report we present 4 year-old boy with ALL-L1 who has complex chromosomal rearrangements. Chromosome analysis was performed on bone marrow aspiration sample in relaps after one year from diagnosis and induction chemotherapy. The karyotype was; 46,XY,t(3;17)(q23;p13),t(5;12)(q31;p13),inv(11)(p15q12) [11]/46,XY[8].

15.
J Matern Fetal Neonatal Med ; 20(8): 627-9, 2007 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-17674281

RESUMEN

Activated recombinant factor VIIa was administered to a preterm infant with bleeding diasthesis and a huge subdural hematoma that could not be controlled by the blood products. The coagulation tests were normalized the following day. Recombinant factor VIIa can be a choice in selected cases with intractable bleedings unesponsive to conventional replacement therapy.


Asunto(s)
Hemorragia Cerebral/terapia , Factor VII/uso terapéutico , Hematoma Subdural/terapia , Enfermedades del Prematuro/terapia , Transfusión de Componentes Sanguíneos , Factor VIIa , Humanos , Recién Nacido , Recien Nacido Prematuro , Masculino , Plasma , Proteínas Recombinantes/uso terapéutico
16.
Onco Targets Ther ; 10: 3299-3306, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28740405

RESUMEN

Achieving lower morbidity and higher survival rates in the treatment of childhood leukemia has been a paradigm of success in modern oncology. However, serious long-term health complications occur in very large populations of childhood leukemia survivors, in the case of both acute lymphoid leukemia and acute myeloid leukemia (AML). Additionally, 15% of acute lymphoid leukemia patients have treatment failures, and rates are even higher in childhood AML. In the last few decades, as a result of well-tested experiments that statistically analyzed treatment cohorts, new agents have emerged as alternatives or supplements to established treatments, in which high survival and/or less morbidity were observed. This review provides an overview of better practice in the treatment of childhood leukemia.

17.
J Cancer Res Ther ; 13(2): 284-290, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28643749

RESUMEN

BACKGROUND: The national protocol aimed to improve the outcome of the high risk neuroblastoma patients by high-dose chemotherapy and stem cell rescue with intensive multimodal therapy. MATERIALS AND METHODS: After the 6 induction chemotherapy cycles, patients without disease progression were nonrandomly (by physicians' and/or parent's choices) allocated into two treatment arms, which were designed to continue the conventional chemotherapy (CCT), or myeloablative therapy with autologous stem cell rescue (ASCR). RESULTS: Fifty-six percent (272 patients) of patients was evaluated as high risk. Response rate to induction chemotherapy was 71%. Overall event-free survival (EFS) and overall survival (OS) at 5 years were 28% and 36%, respectively. "As treated" analysis documented postinduction EFS of 41% in CCT arm (n = 138) and 29% in ASCR group (n = 47) (P = 0.042); whereas, OS was 45% and 39%, respectively (P = 0.05). Thirty-one patients (11%) died of treatment-related complications. CONCLUSION: Survival rates of high-risk neuroblastoma have improved in Turkey. Myeloablative chemotherapy with ASCR has not augmented the therapeutic end point in our country's circumstances. The adequate supportive care and the higher patients' compliance are attained, the better survival rates might be obtained in high-risk neuroblastoma patients received myeloablative chemotherapy and ASCR.


Asunto(s)
Neuroblastoma/terapia , Adolescente , Adulto , Niño , Preescolar , Protocolos Clínicos , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Neuroblastoma/tratamiento farmacológico , Trasplante de Células Madre , Acondicionamiento Pretrasplante , Turquía , Adulto Joven
18.
Nat Genet ; 47(9): 1020-1029, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26214592

RESUMEN

TCF3-HLF-positive acute lymphoblastic leukemia (ALL) is currently incurable. Using an integrated approach, we uncovered distinct mutation, gene expression and drug response profiles in TCF3-HLF-positive and treatment-responsive TCF3-PBX1-positive ALL. We identified recurrent intragenic deletions of PAX5 or VPREB1 in constellation with the fusion of TCF3 and HLF. Moreover somatic mutations in the non-translocated allele of TCF3 and a reduction of PAX5 gene dosage in TCF3-HLF ALL suggest cooperation within a restricted genetic context. The enrichment for stem cell and myeloid features in the TCF3-HLF signature may reflect reprogramming by TCF3-HLF of a lymphoid-committed cell of origin toward a hybrid, drug-resistant hematopoietic state. Drug response profiling of matched patient-derived xenografts revealed a distinct profile for TCF3-HLF ALL with resistance to conventional chemotherapeutics but sensitivity to glucocorticoids, anthracyclines and agents in clinical development. Striking on-target sensitivity was achieved with the BCL2-specific inhibitor venetoclax (ABT-199). This integrated approach thus provides alternative treatment options for this deadly disease.


Asunto(s)
Proteínas de Fusión Oncogénica/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Animales , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Técnicas de Cocultivo , Estudios de Cohortes , Análisis Mutacional de ADN , Resistencia a Antineoplásicos , Femenino , Expresión Génica , Estudios de Asociación Genética , Genómica , Humanos , Inmunoglobulina de Cadenas Ligeras Subrogadas/genética , Concentración 50 Inhibidora , Estimación de Kaplan-Meier , Masculino , Ratones Endogámicos NOD , Ratones SCID , Mutación , Proteínas de Fusión Oncogénica/metabolismo , Factor de Transcripción PAX5/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidad , Eliminación de Secuencia , Ensayos Antitumor por Modelo de Xenoinjerto
19.
Turk J Pediatr ; 44(2): 148-51, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12026205

RESUMEN

Purpura fulminans is a rare but dramatic disease which occurs most commonly during or after an infection. It is characterized by extensive involvement of the skin and extremities and involvement of visceral organs. Purpura fulminans, when occurring after a viral infection such as varicella, is usually characterized by purpuric lesions involving the trunk, usually with sparing of the visceral organs. In this report we describe a child with purpura fulminans due to a transient protein C deficiency as a complication of chickenpox infection. A seven-year-old girl developed bruise-like lesions on her extremities on the fifth day after eruption of varicella exanthem. She had no previous history of bleeding tendency or thrombosis. Family history was also negative. On the seventh day of her illness she was admitted to Marmara University Hospital with widespread echymotic an partially crusted chickenpox lesions. CBC, urinalysis and blood chemistries were within normal limits. She had a prolonged aPT and apt with low serum fibrinogen and high D-dimers suggestive disseminated intravascular coagulation (DIC). Protein C activity was low. Punch skin biopsy was consistent with purpura fulminans. She was treated with heparin and fresh frozen plasma which helped her to recover clinically as well as hematologically. She was discharged with still low protein C activity that returned to normal by the next follow-up visit.


Asunto(s)
Varicela/complicaciones , Vasculitis por IgA/etiología , Deficiencia de Proteína C/complicaciones , Anticoagulantes/uso terapéutico , Transfusión de Componentes Sanguíneos , Niño , Femenino , Productos de Degradación de Fibrina-Fibrinógeno/análisis , Heparina/uso terapéutico , Humanos , Vasculitis por IgA/diagnóstico , Vasculitis por IgA/terapia , Tiempo de Protrombina
20.
Turk J Pediatr ; 44(2): 156-9, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12026207

RESUMEN

Pleuropulmonary blastoma (PPB) is known to be the pulmonary blastoma of childhood. It has a range of macroscopic and microscopic features which appear to correlate with eventual prognosis. Type 1, presenting as a multicystic lesion, occurs at an earlier age and has a more favorable prognosis than other types. The presented case of type 1 PPB had a microscopic focus of rhabdomyosarcoma. Although this patient was disease-free one year after the initial diagnosis without chemotherapy, he presented at 14 months with local dissemination and cardiac metastasis, revealing the inevitable chemo-radiotherapy need in PPB.


Asunto(s)
Neoplasias Pulmonares/diagnóstico , Neoplasias Primarias Múltiples/diagnóstico , Neoplasias Pleurales/diagnóstico , Blastoma Pulmonar/diagnóstico , Rabdomiosarcoma Embrionario/diagnóstico , Preescolar , Quistes/diagnóstico , Diagnóstico Diferencial , Resultado Fatal , Humanos , Inmunohistoquímica , Neoplasias Pulmonares/complicaciones , Masculino , Neoplasias Pleurales/complicaciones , Blastoma Pulmonar/complicaciones , Rabdomiosarcoma Embrionario/complicaciones , Síndrome de la Vena Cava Superior/etiología , Tomografía Computarizada por Rayos X
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA